Jennifer S Buell, President and Chief Executive Officer at MiNK Therapeutics, shared a post on LinkedIn by MiNK Therapeutics, adding:
“Thrilled to welcome COL (Ret.) John Holcomb, to our Board of Directors.
Dr. Holcomb has saved lives on battlefields, transformed trauma care worldwide, and bridged military medicine with global health systems. His voice at MiNK Therapeutics comes at a defining moment, as we build on observed survival advantages and the potential to prevent secondary infections in clinical trials (Hammond et al. Nature Comms), advancing iNKT cell therapies toward late-stage development in pulmonary critical care and cancer.
Innovation is only as strong as the leadership guiding it – and we are honored to have one of the world’s foremost leaders in trauma and critical care join our mission.”
Quoting MiNK Therapeutics‘s post;
“We’re thrilled to welcome COL (Ret.) John B. Holcomb, MD, FACS, to our Board of Directors.
Dr. Holcomb is a global authority in trauma and critical care – with a distinguished career as a U.S. Army trauma surgeon, Commander of the U.S. Army Institute of Surgical Research, and a leader in military and civilian healthcare innovation. He has authored 780+ peer-reviewed publications and brings unmatched insight at the intersection of immune activation, translational science, and global health systems.
As MiNK enters a pivotal phase of late-stage development for iNKT cell therapies in ARDS, trauma-related illness, and cancer, Dr. Holcomb’s guidance will be instrumental.
We are honored to have him join us on this mission.
Read the full announcement.”
More posts featuring Jennifer S Buell on OncoDaily.